The EPS beat and positive SOL-1 data provide near-term bullish momentum, but the revenue miss and widening losses are concerning. Watch for AXPAXLI NDA submission updates and SOL-R data in Q1 2027; the June Investor Day could be a catalyst for regulatory clarity.
OCUL drugs
OCUL drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 5 $9.71entry
- T+1 · 7mo ago 0.00%α −1.38% · $9.71
- T+5 · 6mo ago −4.43%α −6.41% · $9.28
- T+20 · 6mo ago −14.42%α −19.37% · $8.31
- T+60 · 4mo ago −12.77%α −15.51% · $8.47
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ocular Therapeutix reported Q1 2026 EPS of -$0.29, beating consensus of -$0.32 by 9.4%, while revenue of $10.8M was below the $12.7M estimate. The beat was driven by lower-than-expected operating expenses, but the net loss widened to -$88.6M from -$64.1M YoY due to increased R&D spending on AXPAXLI trials. The stock will move on the EPS beat and positive SOL-1 data momentum, offset by revenue miss and cash burn concerns.
Key Financial Metrics
Key Facts
- EPS of -$0.29 beat consensus of -$0.32 by 9.4%
- Revenue of $10.8M missed consensus of $12.7M by 15%
- Net loss widened to -$88.6M from -$64.1M YoY
- Cash balance $666.7M, expected runway into 2028
- AXPAXLI NDA submission for wet AMD on track, subject to FDA discussions
- SOL-R Phase 3 topline data expected Q1 2027
- Investor Day scheduled for June 17, 2026
Financial Impact
EPS beat of $0.03 vs consensus, revenue miss of $1.9M, net loss increase of $24.5M YoY
Risk Factors
- Revenue miss of 15% vs consensus signals DEXTENZA growth stagnation
- R&D spend increased 54% YoY, pressuring cash runway despite $666.7M balance
- AXPAXLI NDA submission and FDA review timeline remain uncertain
- SOL-R non-inferiority trial may not replicate SOL-1 superiority results
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287510 |
Track record
20 reports on OCUL
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +24.88% at T+20 after the Aug 3, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $6.66 Now $6.01 −9.76% settles Nov 18
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $6.85 to $6.01 Now $6.01 −12.26% ▼ −12.26% −10.57% vs SPY
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $6.85 to $6.01 Now $6.01 +12.26% ▲ +12.26% +10.57% vs SPY
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $6.60 to $6.21 Now $6.01 −8.87% ▼ −5.84% −8.43% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.29 to $6.47 Now $6.01 −4.45% ▲ +2.86% +3.01% vs SPY
- Oct 8, 20265w ago 144 Neutral 2/10 Entry $7.54 to $6.87 Now $6.01 −20.29% ▼ −8.89% −6.92% vs SPY
- Sep 2, 202610w ago Insider Cluster Neutral 4/10 Entry $10.64 to $10.49 Now $6.01 −43.52% ▼ −1.41% −0.26% vs SPY
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $10.82 to $10.64 Now $6.01 −44.45% ▼ −1.66% −1.93% vs SPY
- Aug 3, 202615w ago 8-K Bullish 7/10 Entry $8.40 to $9.24 Now $6.01 −28.45% ▲ +10.00% +7.97% vs SPY
- Jun 17, 202621w ago Press Release Bullish 6/10 Entry $9.64 to $9.85 Now $6.01 −37.66% ▲ +2.18% +3.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers